A detailed history of Jpmorgan Chase & CO transactions in Sutro Biopharma, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 58,242 shares of STRO stock, worth $214,912. This represents 0.0% of its overall portfolio holdings.

Number of Shares
58,242
Previous 48,742 19.49%
Holding current value
$214,912
Previous $275,000 38.18%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$2.92 - $5.33 $27,740 - $50,635
9,500 Added 19.49%
58,242 $170,000
Q1 2024

May 10, 2024

SELL
$3.27 - $5.65 $56,891 - $98,298
-17,398 Reduced 26.3%
48,742 $275,000
Q4 2023

Feb 12, 2024

SELL
$2.07 - $4.54 $22,115 - $48,505
-10,684 Reduced 13.91%
66,140 $283,000
Q3 2023

Nov 14, 2023

BUY
$3.29 - $4.9 $6,958 - $10,363
2,115 Added 2.83%
76,824 $266,000
Q2 2023

Aug 11, 2023

BUY
$4.25 - $5.88 $12,920 - $17,875
3,040 Added 4.24%
74,709 $347,000
Q1 2023

May 18, 2023

BUY
$4.48 - $8.45 $185,010 - $348,959
41,297 Added 135.97%
71,669 $331,000
Q1 2023

May 11, 2023

SELL
$4.48 - $8.45 $705,178 - $1.33 Million
-157,406 Reduced 83.83%
30,372 $140,000
Q4 2022

Feb 13, 2023

BUY
$5.41 - $8.08 $174,207 - $260,184
32,201 Added 20.7%
187,778 $1.52 Million
Q3 2022

Nov 14, 2022

SELL
$5.17 - $7.11 $4,415 - $6,071
-854 Reduced 0.55%
155,577 $864,000
Q2 2022

Aug 11, 2022

SELL
$3.41 - $8.95 $48,882 - $128,298
-14,335 Reduced 8.39%
156,431 $815,000
Q1 2022

May 11, 2022

BUY
$7.78 - $15.31 $891,665 - $1.75 Million
114,610 Added 204.09%
170,766 $1.4 Million
Q4 2021

Feb 10, 2022

SELL
$14.25 - $23.53 $8,022 - $13,247
-563 Reduced 0.99%
56,156 $836,000
Q3 2021

Nov 12, 2021

BUY
$16.88 - $22.38 $957,416 - $1.27 Million
56,719 New
56,719 $1.07 Million

Others Institutions Holding STRO

About SUTRO BIOPHARMA, INC.


  • Ticker STRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,161,500
  • Market Cap $192M
  • Description
  • Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-dr...
More about STRO
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.